Total Payments
$14,999
2024 Payments
$116.20
Companies
25
Transactions
78
Medicare Patients
725
Medicare Billing
$170,308

Payment Breakdown by Category

Research$11,968 (79.8%)
Food & Beverage$1,561 (10.4%)
Consulting$1,250 (8.3%)
Education$219.71 (1.5%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $11,968 4 79.8%
Food and Beverage $1,561 70 10.4%
Consulting Fee $1,250 1 8.3%
Education $219.71 3 1.5%

Payments by Type

Research
$11,968
4 transactions
General
$3,031
74 transactions

Top Paying Companies

Company Total Records Latest Year
Celgene Corporation $13,316 5 $0 (2019)
Amgen Inc. $366.05 13 $0 (2018)
Novartis Pharmaceuticals Corporation $235.22 6 $0 (2019)
AbbVie, Inc. $113.03 5 $0 (2018)
Takeda Pharmaceuticals U.S.A., Inc. $110.84 3 $0 (2018)
Ipsen Biopharmaceuticals, Inc $101.44 3 $0 (2018)
Astellas Pharma US Inc $99.95 1 $0 (2024)
Genentech USA, Inc. $93.38 5 $0 (2018)
Daiichi Sankyo Inc. $85.60 5 $0 (2018)
Taiho Oncology, Inc. $68.59 5 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $116.20 2 Astellas Pharma US Inc ($99.95)
2023 $42.93 2 Seagen Inc. ($23.12)
2019 $2,330 2 Celgene Corporation ($2,310)
2018 $5,876 46 Celgene Corporation ($4,767)
2017 $6,633 26 Celgene Corporation ($6,240)

All Payment Transactions

78 individual payment records from CMS Open Payments — Page 4 of 4

Date Company Product Nature Form Amount Type
03/28/2017 Ferring Pharmaceuticals Inc. FIRMAGON (Drug) Food and Beverage In-kind items and services $16.09 General
Category: UROLOGY
03/10/2017 Amgen Inc. Neulasta (Biological), Vectibix Food and Beverage In-kind items and services $23.43 General
Category: Oncology
02/07/2017 Bayer HealthCare Pharmaceuticals Inc. Nexavar (Drug), Stivarga Food and Beverage In-kind items and services $16.29 General
Category: Oncology

Research Studies & Clinical Trials

Study Name Company Amount Records
ABI-007-PANC-007 Celgene Corporation $4,867 1
ABI-007-PANC-007 - nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). Celgene Corporation $4,767 1
nab1-paclitaxel (Abraxane) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, Phase 2 study (LAPACT). (ABI-007-PANC-007) Celgene Corporation $2,310 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 143 438 $251,114 $38,579
2022 4 116 277 $166,415 $26,756
2021 7 202 567 $327,080 $60,214
2020 8 264 542 $218,524 $44,759
Total Patients
725
Total Services
1,824
Medicare Billing
$170,308
Procedure Codes
26

All Medicare Procedures & Services

26 procedure records from CMS Medicare Utilization — Page 2 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99213 Established patient office or other outpatient visit, typically 15 minutes Facility 2020 13 16 $4,900 $511.55 10.4%

About Dr. Jennifer Chuy, MD

Dr. Jennifer Chuy, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2010. The National Provider Identifier (NPI) number assigned to this provider is 1174826531.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Chuy, MD has received a total of $14,999 in payments from pharmaceutical and medical device companies, with $116.20 received in 2024. These payments were reported across 78 transactions from 25 companies. The most common payment nature is "" ($11,968).

As a Medicare-enrolled provider, Chuy has provided services to 725 Medicare beneficiaries, totaling 1,824 services with total Medicare billing of $170,308. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.

Practice Information

Products in Payments

  • Abraxane (Drug) $13,316
  • NINLARO (Drug) $123.56
  • SANDOSTATIN LAR (Drug) $120.80
  • XGEVA (Biological) $103.26
  • JADENU (Drug) $94.24
  • Avastin (Biological) $93.38
  • Neulasta (Biological) $93.18
  • INJECTAFER (Drug) $85.60
  • Lonsurf (Drug) $68.59
  • Creon (Drug) $66.17
  • OPDIVO (Biological) $58.52
  • Venclexta (Drug) $46.86
  • Kyprolis (Biological) $35.78
  • Lenvima (Drug) $34.01
  • Aranesp (Biological) $33.88
  • FIRMAGON (Drug) $31.96
  • KEYTRUDA (Biological) $31.65
  • Folotyn (Drug) $27.79
  • XALKORI (Drug) $25.75
  • JEVTANA (Drug) $24.31

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Bronx